Organic Active Ingredients TRIZ Cases

Fc-containing formats pair anti-HLA-A2/NY-ESO binding with longer circulation, addressing the short half-life of Fc-free bispecific antibodies.

Using 212Pb with a PSMA-targeting ligand, this case addresses salivary-gland uptake and xerostomia while treating prostate cancer.

A 9-nucleoside modified oligonucleotide targets upregulated miR-17 family members to slow PKD cyst growth and improve kidney function.

Conventional glioblastoma treatments have not improved survival; subtype-targeted miRNA combinations inhibit tumor growth and aggressiveness.

Selective 17βHSD13 inhibition targets a liver-disease pathway directly, rather than only managing obesity, diabetes, or dyslipidemia.

Current Aβ-focused therapies show limited effect; grapevine stem extract targets HSV-1, amyloid beta, and tau phosphorylation.

An amino acid and peptide composition helps lower liver-damage markers and reduce oxidative stress and inflammation after drug exposure.

Low-dose mifepristone blocks glucocorticoid receptors to improve insulin sensitivity while limiting cortisol elevation and HPA-axis activation.

A PNP hydrogel accommodates immunomodulatory cargos of different sizes and chemical natures for coordinated local release.

Covalent orthosteric compounds target HER2 exon 20 mutant kinases while sparing EGFR wild type to address dose-limiting toxicity.

Changing cholesterol oxidation sites tunes nanoparticle tropism, directing therapeutic RNA toward liver non-hepatocytes such as Kupffer and endothelial cells.

Existing MNK inhibitors enable target verification but lack clinical application; this case develops polycyclic compounds for MNK1/MNK2 inhibition.

Penetration enhancers such as DMSO and diethyleneglycol monoethyl ether help endoxifen cross skin while limiting systemic exposure.

Substituted thienopyrrole compounds target TLR7 and TLR8 while addressing potency and pharmacokinetic stability in lupus therapy.

Novel Compound 1 salts and crystalline forms improve solubility and bioavailability, supporting lower doses and fewer side effects.

Minoxidil and finasteride can cause side effects and slow results; pulchinenoside B4 or B5 supports rapid hair growth without toxic effects.

Exercise and nutritional supplements have limited efficacy for liver-disease sarcopenia; rifaximin adds a pharmacological option linked to muscle gains.

See how cyclodextrin complexation improves furosemide solubility and stability at physiological pH for subcutaneous or intravenous delivery.

Targeted RNA agents inhibit myeloid activation factors to reduce retinal neovascularization in AMD, ROP, and diabetic retinopathy.

Dry powder inhalation uses diketopiperazine particles to deliver a kinase inhibitor to lung tissue while reducing gastrointestinal and hepatobiliary side effects.

Chemical derivatives target MRGX2 to limit mast cell degranulation and inflammation in atopic dermatitis, chronic urticaria, and asthma.

Trimeprazine offers a treatment approach for chronic trigeminal neuralgia when conventional pain relief loses effectiveness over time.

Novel STK17A inhibitor compounds are developed for SF3B1-mutated malignancies, leukemia, and myelodysplastic syndromes.

Tau-selective compounds avoid photoisomerization while supporting accurate detection of deposits in in vitro and in vivo applications.

Conventional therapies can leave resistant cancer stem cells behind; selective CDK4/6 inhibition targets CSC proliferation to limit recurrence and metastasis.

Selective PARP1 compounds spare PARP2 to address blood and gastrointestinal side effects while supporting blood-brain barrier penetration.

Protein-bound tryptophan particles use α-lactalbumin interactions to improve stability and bioavailability while reducing bitterness in food products.

A breakable seal separates the lyophilized product from its reconstituting solution until mixing, reducing handling and exposure risks.

RAC1 inhibitors provide an alternative molecular pathway for bronchodilation when severe asthma needs more than conventional corticosteroids and beta-2 agonists.

Quinoline-substituted isoindolinone compounds bind CRBN and induce Ikaros/Aiolos and GSPT1 degradation for therapeutic use.

Volatile silicone fluid helps drug nanoparticles cross the stratum corneum while limiting irritation and systemic absorption.

Traditional copper chelators can lack metal specificity and cause toxicity; this case uses tetradentate ligands to selectively deplete copper in cancer cells.

An electrophilic pyrimidine compound enables covalent FGFR1 kinase binding to address mutant resistance and inhibit lung cancer cell proliferation.

USP14-binding chimeras recruit CERT to the 26S proteasome without E3 ligases, depleting the target and sensitizing cancer cells to HER2 therapy.

An immediate-release ivermectin–albendazole combination enables water-free dosing and helps limit resistance risk in helminth treatment.

Measure Clostridium hiranonis and related gut microbes against reference abundances to identify dogs responsive to hydrolyzed protein diets for chronic enteropathy.

Existing routes struggle to produce suitable crystalline drug forms; controlled solvents, temperature, and pH enable pharmaceutical-grade compounds.

Specific substituents and heteroatoms tune the fused bicyclic structure toward PARP1 selectivity, reduced toxicity, and chemotherapy compatibility.

Existing HBV drugs can suppress viral DNA without clearing HBsAg; this compound adds immune activation to pursue functional cure.

Pulmonary microparticles help deliver triptans rapidly while limiting peripheral and vascular degradation in migraine treatment.

See how fed-state dosing with naltrexone and bupropion addresses food-effect gaps, raising Cmax by 91–271% and AUC by 70–107%.

Controlled cooling and anti-solvent addition produce TETA.4HCl Form B with improved room-temperature stability and less humidity sensitivity.

Limited antiviral efficacy is addressed with 2′,3′-dihydroxy-4′-fluoromethyl nucleosides for Flaviviridae and Pneumoviridae infections.

An enteric coating holds the PRS inhibitor in acidic gastric conditions and releases it in the intestine to reduce nausea and vomiting.

Nuclease degradation and poor cellular uptake limit nucleic acid medicines; multibranched lipids protect and deliver them for gene silencing.

Lipo-hydroxamic acid derivatives convert into lipoic acid for topical use, improving corneal absorption while limiting mucosal irritation.

Chemical modification of saponins supports endosomal toxin release while reducing cytotoxicity and hemolytic activity for a wider therapeutic window.

Warm-microbiota strains such as Parabacteroides modulate gut bacteria and increase bone density in osteoporosis treatment.

Late acetaminophen injury can outlast N-acetyl cysteine’s treatment window; pre-polarized macrophages reduce necrosis and support liver regeneration.

Blocking CYP26 raises atRA levels, enhancing mitochondrial biogenesis and neuronal growth in SURF1-dependent Leigh syndrome.

Replacing petroleum fats with renewable polytrimethylene ether glycol eliminates sticky skin feel while maintaining effective moisturization.

Humanized anti-TNF antibodies with specific heavy and light chains reduce immunogenicity while maintaining therapeutic effectiveness against TNF-alpha.

Afatinib fumarate salt formation resolves polymorphism instability while improving dissolution profiles and manufacturing consistency.

Double ligation reaction links protein domains using cysteine transpeptidase enzymes for chemoselective insertion.

Developing novel ARN-509 polymorphs CS8 and CS9 resolves poor solubility and grinding instability in prostate cancer drug manufacturing.

A pressure-sensitive adhesive mixture of polyisobutylene and a silicon-containing polymer facilitates transdermal fentanyl delivery.

Topical agents restore impaired skin physiology via PKC modulators and adipokines, overcoming structural impairments in diabetic and aged tissue.

Measuring IL2RA, IGF2BP1, and TNFRSF12A polymorphisms differentiates ASD-associated ileocolitis from conventional inflammatory bowel diseases.

Neutral human milk oligosaccharides repair the mucosal barrier and reduce inflammation, addressing side effects from conventional antidepressants.

Segmented tetracyclic heterocycle compounds target the NS5B polymerase to resolve insufficient selective inhibition of viral replication in current therapies.

Bis-cyclic piperazine inhibitors resolve specificity issues in protein palmitoylation targeting.

Replacing scarce marine isolation with synthetic analogues that retain the 16-membered macrolactone pharmacophore while simplifying molecular complexity.

Oral ketamine formulations use specific excipients to enable rapid API release, resolving the trade-off between patient convenience and bioavailability.

Deuterated AZD9291 mesylate crystal form overcomes EGFR T790M mutation resistance by increasing blood-brain barrier penetration via deuterium substitution.

Differentiating induced pluripotent stem cells into purified hypothalamic neurons enables scalable exosome production that crosses the blood-brain barrier.

Albiflorin replaces combination drug regimens to treat irritable bowel syndrome, reducing side effects and cost while maintaining comprehensive efficacy.

CMP-KDN analogs inhibit bacterial sialyltransferase to block complement evasion, addressing antibiotic resistance in Neisseria gonorrhoeae.

A mucolytic tablet composition using N-acetyl-L-cysteine with buffering agents to reduce biological sample viscosity.

Tricyclic quinazoline-2-one compounds target oncogenic RAS mutants via localized molecular recognition, resolving selectivity challenges in cancer therapy.

Magnesium stearate forms a film on triamterene particles during mixing, reducing bioavailability and eliminating hyperkalemia risks without surfactants.

Segmented microneedles distribute filler composition locally to resolve pain and material waste in skin treatments.

Selective 15-PGDH inhibitors block enzymatic inactivation of prostaglandins, resolving the trade-off between detoxification capability and tissue repair.

A composite antioxidant formulation combines pollen, royal jelly, and vitamins to provide comprehensive protection.

Novel SSAO inhibitor reduces inflammatory responses by blocking semicarbazide-sensitive amine oxidase activity, offering effective pain relief.

Lipofullerene conjugates rejuvenate inactive follicles by increasing ATP production, addressing ineffective treatments with side effects.

Analyzing CD8+ T-cell subsets and cytokine levels identifies patients at risk for delayed bone fracture healing, enabling targeted supportive therapies.

Novel cationic lipids form lipid nanoparticles to protect nucleic acids from plasma nuclease digestion while enabling efficient intracellular uptake.

A sugammadex pharmaceutical composition undergoes pH adjustment to 7.5-8.0 followed by filtration through a 0.45 μm pore filter.

A solid pharmaceutical form uses a three-polymer mixture to create a transient gelled barrier that delays active ingredient release without film coating.

Combining BCAAs with L-Alanyl-L-alanine prevents muscle wasting by enhancing protein synthesis while reducing catabolism during intense exercise.

Pyrimidinone carboxamide compounds inhibit endothelial lipase to treat dyslipidemias.

Apremilast formulation uses direct compression with microcrystalline cellulose and lactose to create a stable immediate release dosage.

Alkyl esterified dihydrotetrabenazine compounds conjugate with fatty acids to produce stable prodrugs.

A hyaluronic acid and inorganic peroxide composition releases oxygen to provide sustained antibacterial activity.

WES and single-cell RNAseq detect CTCL mutations, resolving precision complexity trade-offs for targeted therapy.

Unified HPLC procedure detects trifluridine, tipiracil, and 2-deoxy-5-methoxycarbonyluridine simultaneously, eliminating separate analytical steps.

Substituted piperazine derivatives inhibit VDAC oligomerization to treat central nervous system disorders.

Chemically modified RNA agents activate natural killer cells via ZC3H12D binding to suppress tumor metastasis.

A ginseng ferment composition mixes ethanol extract with fruit and vegetable fermentation solution to enhance immunity.

Pyridine derivatives with heterocyclic rings and amino groups treat azole-resistant fungal infections while reducing mammalian side effects.

Novel ionizable lipids protect nucleic acids from plasma nuclease digestion while enabling efficient intracellular release via pH-responsive endosomal escape.

Targeted mutations in loop1, alpha-helix, and random coil regions preserve catalytic activity during bloodstream transit.

Direct crystallization from organic solvents eliminates tartaric acid co-crystallization complexity, improving manufacturing reproducibility for ABT-888.

Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione compounds suppress nonsense mutations through targeted structural modifications.

Composite polymer coatings on segmented beads maintain drug release for 8 to 12 hours while preventing dose dumping.

Antibodies binding PD-1 receptors deliver activating signals to immune cells, enhancing cytokine production and T cell proliferation.

Melanin-based mouth inserts absorb radiation to prevent oral mucositis during cancer therapy.

Gamma-AAPeptides activate PTEN to inhibit the PI3K/AKT/S6K pathway, avoiding off-target effects and drug resistance.

L-arginine releases nitric oxide to dilate blood vessels while niacin accelerates absorption and cooling agents mask irritation.

Anchoring systems in drug depot implants minimize migration from the target site, ensuring sustained therapeutic agent release.

Pharmaceutically acceptable fatty acid carboxylate salts of LXR modulators maintain stability and bioavailability over time.

Cationic progesterone lipid derivatives inhibit the PI3K/AKT pathway to overcome resistance in both progesterone receptor-positive and negative cancer cells.

An alpha-7 nicotinic acetylcholine receptor agonist restores cystic fibrosis transmembrane conductance regulator ion transport.

HIPS chemistry achieves homogenous antibody-drug conjugates with controlled ratios, resolving heterogeneity from random protein modification.

Mixing active ingredients with oversized excipients achieves high content uniformity in solid formulations.

Selective USP30 inhibitors modulate mitochondrial function and resolve toxicity trade-offs in cancer and fibrosis treatments.

A novel imidazothiadiazole derivative compound inhibits metastatic cancer cell growth while sparing healthy epithelial cells.

Polymer particles with functional groups bind copper in the gut, reducing organ accumulation and avoiding side effects from traditional chelators.

Merges PARP inhibition with immune checkpoint therapy to kill BRCA-mutant cells while minimizing systemic toxicity.

Axial release means transmits force to counteract reactive loads, maintaining consistent piston plate speed for reliable microneedle insertion.

Master regulator immunotherapy inhibits glioblastoma stem-like cells to address cellular heterogeneity and reduce toxicity to normal neuronal precursor cells.

Modified 4-methylumbelliferone compounds overcome poor bioavailability to reduce inflammation and fibrosis in primary sclerosing cholangitis.

Specific heparan sulphate sequences bind BMP2 to prolong signaling effects and resolve unclear GAG interaction mechanisms.

Ionic interactions trigger peptidomimetic self-assembly to form stable hemostatic barriers, resolving bleeding control without thermal tissue damage.

Novel bridged tricyclic carbamoylpyridone compounds inhibit HIV integrase to reduce viral replication.

Bio-soluble microneedle assembly delivers active ingredients into skin tissue, resolving pain and stability issues in current treatments.

Bicyclic compounds modulate S1P1 receptor activity via localized substituent placement, reducing pulmonary side effects while maintaining therapeutic efficacy.

HER3 pulsed dendritic cells stimulate CD4 and CD8 T cell responses, resolving incomplete tumor regression from peptide vaccines.

Purified Withaferin A compounds resolve the trade-off between weight loss efficacy and safety side effects associated with conventional obesity medications.

NI-0501 neutralizes interferon-gamma to reduce toxicity in hemophagocytic lymphohistiocytosis.

Pyridone derivatives modulate MCH receptors to treat obesity and metabolic disorders while improving pharmacokinetic stability.

Selective CRAC channel inhibitors reduce cytokine release and side effects in autoimmune therapy.

Hybridizing a modified RNA oligomer with mRNA creates a stable double-stranded carrier that induces strong cellular and humoral immunity without requiring adjuvants.

Selected reaction monitoring mass spectrometry quantifies specific tumor peptides to guide targeted lung cancer therapy selection.

Substituted imidazo naphthyridine compounds inhibit ENPP1 to enhance STING pathway activation and stimulate anti-tumor immune responses.

Novel peptide sequences bind MHC molecules to induce targeted T-cell responses against tumor cells.

Merges BT1718 with PD-1 or CTLA-4 antibodies to overcome insufficient single-agent MT1-MMP inhibition.

Fused heteroaryl compounds modulate sodium ion channels, resolving inadequate specificity in existing treatments.

Phenyl-guanidine derivatives block Rac1 interaction with guanosine exchange factors to inhibit protein activity.

Plant steroid drug conjugates link corticosteroids to sterols via digestion-resistant bonds, preventing systemic absorption and reducing adverse side effects.

Chitobiomers and T-ChOS compositions enable enhanced bioavailability through optimized enzymatic hydrolysis.

NHE-1 inhibitors restore ion homeostasis to reduce viral load, preventing cardiotoxic effects and cytokine storms in coronavirus infections.

Segmented layers control dissolution rates so the masking component outlasts the active ingredient release to eliminate bitter aftertaste.

Benzimidazole cyclic dinucleotides enhance membrane permeability through lipophilic nucleobase substitution.

A pharmaceutical formulation combines a pyridinium compound with a permeability enhancer and base to boost oral bioavailability.

An XPO1 inhibitor sensitizes small cell lung cancer tumors to chemotherapy by targeting exportin-1 expression levels.

A pharmaceutical compound protects stem cells from inflammatory environments while restoring mitochondrial function.

Chimeric antigen receptors on T cells target B-cell maturation antigen to overcome therapy resistance and prevent multiple myeloma relapse.

MTA-cooperative inhibitors target PRMT5 in MTAP-deficient cancers, converting elevated MTA levels into selective therapeutic vulnerability.

Bicyclic bis-heteroaryl derivatives inhibit protein aggregation by targeting toxic oligomers.

Optimized V-groove dimensions prevent random peeling and ensure clean, uniform film separation during tablet splitting.

Formula I compounds alleviate visceral pain in irritable bowel syndrome by targeting aberrant RET kinase activity.